Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded down 19.4% on Thursday . The company traded as low as C$0.14 and last traded at C$0.15. 519,694 shares traded hands during mid-day trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The firm has a fifty day moving average price of C$0.20 and a two-hundred day moving average price of C$0.12. The stock has a market capitalization of C$21.13 million, a PE ratio of -4.23 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What Do S&P 500 Stocks Tell Investors About the Market?
- Hershey’s Sweet Comeback: Why Investors Are Taking Notice
- 3 Small Caps With Big Return Potential
- 3 Reasons Occidental Petroleum Will Gush Higher in 2025
- Financial Services Stocks Investing
- After Earnings, Is Transocean Stock the Best Energy Play?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
